However, to date, it is unclear what role increased ER-beta subtypes plays with regard to ACC tumorigenesis, or the feasibility of estrogen receptor blockage as a therapeutic target for ACC. This evidence concerns the gene ESR1 and adrenal cortex carcinoma.